Abstract
To determine the relation between early stage and exudative AMD and CYP2J2 (-76G>T) gene rs890293 polymorphism in a Lithuanian population. The study enrolled 204 patients with early AMD, 197 patients with exudative AMD and 198 healthy controls. Samples of DNA from peripheral white blood cells were purified using commercial kits. The genotyping was carried out using a real-time PCR method. The CYP2J2 (-76G>T) rs890293 TT genotype in patients with early AMD was statistically significantly less frequent than in the control group: 0% vs. 2.5% (P=0.028). There were no significant differences in rs890293 gene polymorphisms between the exudative AMD and control groups. Also, the CYP2J2 (-76G>T) rs890293 TT genotype was statistically significantly less frequent in older early AMD patients (≥65 years) compared to control group persons (≥65 years): 0% vs. 5.4% (P=0.03). The CYP2J2 (-76G>T) TT genotype may be associated with reduced manifestation of early stage AMD; therefore, a larger sample size is required for further analysis.
Highlights
Age-related macular degeneration (AMD) is damage to the macula which causes significant and irreversible central vision loss in aging patients[1]
Females made up 73.5% (n=150) of the early AMD group, 68.02 % (n=134) of the exudative AMD and 77.8% (n=154) of the control group (P=0.09)
Our study revealed that the CYP2J2 (-76G > T) rs890293 TT genotype was significantly less common in patients with AMD, compared to the control group (P=0.028), and TT polymorphism was significantly less common in older early AMD patients (≥65 years), compared to healthy controls (P=0.03)
Summary
Age-related macular degeneration (AMD) is damage to the macula which causes significant and irreversible central vision loss in aging patients[1]. It is thought that the number of people suffering from AMD will continue to grow, and by 2020 it will have increased up to 196 million, and by 2040 the disease will have damaged visual function of 288 million people[2]. AMD is diagnosed in one third of persons over 75 years. While progressing to late stages, such as central geographic atrophy (GA) and choroidal neovascularization (CVN) (ref.1), AMD causes visual loss in 6-8% of patients[3]. Patient age has one of the greatest effects on the development of AMD (ref.[4])
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
